GHSR1a inverse agonist for appetite suppression
Targeted lipolysis without insulin spike (glucagon arm)
Drive hepatic and adipose lipolysis via glucagon receptor activation while sparing chronic hyperglycemia; tri-agonist or biased GCGR agonism.
The Studio
Peptide design briefs for research review. Browse. Fork. Run Phase 4 on any idea with one click.
3 ideas · seven enhancement lanes · one-click handoff to the effect-driven design pipeline.
🎁 Free tier — 3 brief runs / 24h per IP. Each run produces 3 research briefs. Add an API key for higher quotas.
Tri-agonist with biased β-arrestin signaling
Suppress appetite via central melanocortin axis
Suppress appetite via the central melanocortin pathway with selectivity over peripheral pigmentation receptors; favor MC4R agonism with low MC1R off-target activity.
Oral GLP-1 with reduced albumin binding
Glucose-stimulated insulin secretion (GLP-1 / GIP wedge)
Boost glucose-stimulated insulin secretion and slow gastric emptying via incretin axis; favor dual GLP-1R / GIPR agonism, oral peptide route preferred.